Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RC017
- Development stage
- Phase 1
- Lead developer
- Nanjing Reju Therapeutics
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
RC017 is a novel small-molecule therapeutic candidate developed by Nanjing Reju Therapeutics for the treatment of dry eye disease (DED). Formulated as an ophthalmic ointment, the drug is designed to provide a new therapeutic option for patients suffering from the ocular discomfort and tear film instability associated with DED. It is currently in early-stage clinical development, with Phase 1 studies focusing on evaluating its safety, tolerability, and pharmacokinetic profile in healthy adult participants following both single and multiple doses.
- Other names
- RC017 Ophthalmic OintmentRC-017 Ophthalmic OintmentRC 017 Ophthalmic Ointment
Beyond the preview
Go deeper on RC017.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RC017.